Public Health Foundation of India
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodgers, Anthony
GMRx2_PCT, NCT04518306: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Completed
3
755
Europe, US, RoW
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
George Medicines PTY Limited
Hypertension
09/23
10/23
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Completed
3
1385
Europe, US, RoW
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
George Medicines PTY Limited
Hypertension
08/23
09/23
OPTIMISE-BP, NCT06935760: Optimised Treatment for Hypertension Trial

Not yet recruiting
3
120
RoW
Fire and forget, Usual care with more intensive BP monitoring, More BP measures
The George Institute
Hypertension
12/26
12/26
RAFT-ECT, NCT05402657: The RAFT ECT Study

Recruiting
N/A
154
US, RoW
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
The George Institute, National Health and Medical Research Council, Australia, Ramsay Clinic Albert Road, Australia, Ramsay Clinic Lakeside, Australia, Ramsay Clinic Northside, Australia, Gold Coast Hospital and Health Service, Augusta University, Medical University of South Carolina, The University of New South Wales, Emory University
Major Depressive Episode
08/25
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodgers, Anthony
GMRx2_PCT, NCT04518306: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Completed
3
755
Europe, US, RoW
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
George Medicines PTY Limited
Hypertension
09/23
10/23
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Completed
3
1385
Europe, US, RoW
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
George Medicines PTY Limited
Hypertension
08/23
09/23
OPTIMISE-BP, NCT06935760: Optimised Treatment for Hypertension Trial

Not yet recruiting
3
120
RoW
Fire and forget, Usual care with more intensive BP monitoring, More BP measures
The George Institute
Hypertension
12/26
12/26
RAFT-ECT, NCT05402657: The RAFT ECT Study

Recruiting
N/A
154
US, RoW
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
The George Institute, National Health and Medical Research Council, Australia, Ramsay Clinic Albert Road, Australia, Ramsay Clinic Lakeside, Australia, Ramsay Clinic Northside, Australia, Gold Coast Hospital and Health Service, Augusta University, Medical University of South Carolina, The University of New South Wales, Emory University
Major Depressive Episode
08/25
01/26

Download Options